Aurobindo Pharma Limited stands as India's second-largest listed pharmaceutical company based on revenue and holds the distinction of being the largest generics company in the United States. The company is ranked among the top 10 generic companies in 8 European countries, establishing its significant presence in major global markets. Founded in 1986, Aurobindo Pharma is headquartered in Hyderabad, India, and has evolved into a comprehensive pharmaceutical manufacturing and marketing enterprise.
The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. As the largest generic pharma company in the US by prescriptions dispensed according to MAT March 2024 data, Aurobindo has established a formidable global footprint. The company markets its products globally in approximately 150 countries, demonstrating its extensive international reach.
Aurobindo Pharma operates through a robust manufacturing infrastructure that supports its global operations. The company operates 29 manufacturing facilities across the globe with manufacturing capacities of 50+ billion formulations units and 19,000+ MT APIs. This extensive manufacturing network provides the company with significant scale advantages and advanced vertical integration capabilities to produce finished formulation products at competitive prices.
The company employs 37,596 total employees globally, reflecting its substantial operational scale. Aurobindo is a significant global generics player with 28 manufacturing facilities, including eight key formulations facilities in India and abroad along with three R&D centres. The current employee strength is more than 8000, which includes more than 750 scientists, highlighting the company's strong focus on research and development capabilities.
Aurobindo Pharma operates in several lines of business including APIs, generics, biosimilars, advanced drugs, and consumer healthcare. The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit.
The company's key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products and is developing topical as well as transdermal products in the dermatology therapeutic segment.
For the quarter ended March 2025 (Q4 FY25), Aurobindo Pharma reported revenue of ₹8,381.12 crores and net profit of ₹902.83 crores. The company's net profit fell by 0.58% compared to the same period last year, reaching ₹903.47 crores in Q4 2024-2025, though it showed quarterly growth of 6.82% compared to the previous quarter.
For Q3 FY25, the company's revenue jumped 8.29% year-over-year to ₹8,137.40 crores, while net profit fell 9.66% to ₹845.81 crores compared to the same period last year. The net profit margin for Q3 FY25 stood at 10.39%.
Looking at the annual performance for FY24, operating income rose 16.7% year-over-year, and the company's operating profit increased by 52.0% during the fiscal year. Net profit for FY24 grew by 64.4% year-over-year, with net profit margins improving from 7.8% in FY23 to 10.9% in FY24.
Key financial metrics as of recent reporting periods include:
- Trailing 12-month revenue of $3.64 billion as of December 31, 2024
- Trailing twelve-month earnings per share of ₹54.1, improved from ₹32.9 in the previous year
- Market capitalization of ₹69,173 crores
Aurobindo Pharma has been making significant strides in the biosimilar space, which represents a key growth driver for the company. The company has a strong and sustainable pipeline of high value biosimilar programs with a primary focus on Oncology and Immunology therapeutic segments.
Recent regulatory approvals demonstrate the company's progress in this segment. The company's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzumab biosimilar, following the positive opinion issued by the European Medicines Agency's CHMP in April 2025.
With this latest approval, Dazublys™ becomes CuraTeQ's third EMA-approved biosimilar, following Dyrupeg™ and Zefylti™. It also marks the fourth biosimilar approval for CuraTeQ in the European region, including Bevqolva™, which received approval from the UK's MHRA in December 2024.
The company plans to venture into complex areas like biosimilars, vaccines & complex injectables. Additionally, participation in the PLI scheme will enhance its backward integration in antibiotics and open new revenue streams. Aurobindo is setting up a plant for production of Penicillin-G with capacity of 15,000 MT for ₹1,850 crores under the PLI scheme.
Despite facing potential challenges from US tariffs due to significant revenue exposure, the company is expanding its US presence with a new subsidiary and focusing on biosimilars, targeting a $50 billion market opportunity.
The company has been actively expanding its product portfolio and geographic reach. Production of Penicillin-G was restarted at the Kakinada facility following environmental consent on June 29, 2025, marking an important operational milestone.
Currently, 80.77% of analysts recommend a 'BUY' rating for Aurobindo Pharma, with an average target price of ₹1,393.23. Nuvama Institutional Equities maintains a Buy rating on the company, projecting a 15% profit CAGR through FY27, driven by new product launches and capacity expansions. The stock is seen as undervalued, trading at a discount to historical averages.
However, some challenges remain. The company has delivered a poor sales growth of 6.55% over the past five years and has a low return on equity of 10.2% over the last 3 years. Promoter holding in the company has remained relatively stable at 51.82% as of March 2025.
Aurobindo Pharma continues to strengthen its position as a leading global pharmaceutical company through strategic investments in biosimilars, expansion of manufacturing capabilities, and diversification across therapeutic areas. The company's strong presence in regulated markets, combined with its robust product pipeline and manufacturing excellence, positions it well for future growth despite near-term operational challenges.
